We compared the effects of the two molecular forms of the brain-gut peptide YY (PYY), PYY(1-36) and PYY(3-36), on gastric emptying. Unanesthetized rats received 20-min intravenous infusions of rat PYY(1-36) (0, 1.7, 5, 17, 50, 100, 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) and rat PYY(3-36) (0, 0.5, 1.7, 5, 17, 50, 100, 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ), either alone or combined, and gastric emptying of saline was measured during the last 10 min of infusion. For comparison, human PYY(3-36) was administered at 0, 17, and 50 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 . Gastric emptying was decreased by 11, 24, 26 and 38% in response to 17, 50, 100, and 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 of rat PYY(1-36); by 10, 26, 41, 53, and 57% in response to 5, 17, 50, 100, and 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 of rat PYY(3-36); and by 35 and 53% in response to 17 and 50 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 of human PYY(3-36), respectively. Estimated ED50s were 470 and 37 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 for rat PYY(1-36) and PYY(3-36), respectively. In general, within an experiment, coadministration of PYY(1-36) and PYY(3-36) inhibited gastric emptying by an amount that was comparable to that produced when either peptide was given alone. We conclude that 1) intravenous infusion of PYY(1-36) and PYY(3-36) each produces a dose-dependent inhibition of gastric emptying in rats, 2) PYY(3-36) is an order of magnitude more potent than PYY(1-36) in inhibiting gastric emptying, 3) human PYY(3-36) and rat PYY(3-36) inhibit gastric emptying similarly, and 4) PYY(1-36) and PYY(3-36) do not appear to interact in an additive or synergistic manner to inhibit gastric emptying. intravenous infusion; dose response; interaction PEPTIDE YY (PYY), neuropeptide Y (NPY), and pancreatic polypeptide (PP) comprise the "PP-fold" family of structurally related brain-gut peptides. PYY is synthesized in the gastrointestinal tract, as well as in the central and peripheral nervous systems. Endocrine cells of the ileum, colon, and rectum provide a major source of PYY (2, 47). PYY has also been detected in gastric mucosa, pancreatic islets, myenteric and serosal ganglia, sympathetic neurons, adrenal gland, spinal cord, and brain, including the hypothalamus, pituitary, pons, medulla oblongata, and the brain stem (7-9, 15, 16, 22, 30, 32, 37).
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Food intake releases PYY into the circulation (2, 47) . Systemic administration of PYY inhibits food intake, gastric emptying, intestinal fluid and electrolyte secretion, gallbladder contraction, and exocrine pancreatic secretion (5, 36) . Whether PYY acts physiologically by endocrine, neurocrine, and/or paracrine mechanisms to produce these effects remains to be determined. If PYY acts as a blood-borne hormonal signal to produce an effect, then it is important to determine whether the effect is produced by intravenous doses of PYY that reproduce meal-induced increases in plasma PYY.
The two major molecular forms of PYY found in the gut and circulation are PYY and PYY (19 -21) . In humans, plasma concentrations of PYY were reported to be 11 pM in the fasted state with PYY contributing 37% of the total PYY immunoreactivity. In the postprandial state, plasma PYY levels increased to 49 pM with PYY(3-36) accounting for 54% of total PYY immunoreactivity (19) . In rats, a liquid, mixed-nutrient meal increased plasma PYY from a basal level of 42 pM to a peak of 160 pM within 30 min; plasma PYY then gradually declined to basal levels over a 3-h period (26) . In the same study, an intravenous dose of PYY(1-36) of 0.83 pmol⅐kg Ϫ1 ⅐min Ϫ1 increased plasma PYY by a comparable amount. In anesthetized rats, duodenal infusion of a mixed-nutrient, semiliquid meal increased plasma PYY from 7 pM to a peak of 100 pM by 60 min; duodenal infusion of oleic acid produced a much smaller response (17) . The assays used in these rat studies did not differentiate between PYY(1-36) and PYY .
Postprandial plasma levels of PYY appear to be reproduced in rats by intravenous doses of 0.83 to 2 pmol⅐kg Ϫ1 ⅐min Ϫ1 (26, 46) . In rats, these doses inhibit CCK-8-stimulated pancreatic secretion (26) , ethanol-induced gastric lesions (27) , and thyrotropin-releasing hormone-induced gastric acid secretion (49) . It remains to be determined whether similar doses of PYY(1-36) inhibit gastric emptying; bolus intraperitoneal injection of PYY has been reported to inhibit gastric emptying in rats (40) . Gastric emptying is inhibited in humans (3, 44) and dogs (38) by intravenous doses of PYY , which appear to reproduce postprandial increases in plasma PYY. In contrast, PYY(3-36) was reported to have no effect on gastric emptying in rats or humans (4) . It remains to be determined whether postprandial increases in plasma PYY are sufficient to inhibit gastric emptying in rats or produce other actions attributed to PYY, including inhibition of food intake, gastric acid secretion, and pancreatic secretion. Furthermore, the interactions between both forms of the peptide in influencing food intake and gastrointestinal functions have not been reported.
The aims of the present study were to compare the dosedependent effects of intravenous infusions of PYY and PYY(3-36) on gastric emptying in rats and to examine whether PYY and PYY interact in an additive or synergistic manner to inhibit gastric emptying.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Charles River, Kingston, NY) weighing 300 -485 g were housed individually in hanging wire-mesh cages in a room with controlled temperature (19 -21°C) and a 12:12-h light-dark cycle (lights off at 1700 h). The animals were provided pelleted rat chow (Labdiet, 5001 Rodent diet; PMI Nutrition International, Brentwood, MO) and water ad libitum. The Animal Studies Subcommittee of the Omaha Veterans Affairs Medical Center approved the experimental protocol. Animal experimentation was conducted in conformity with the "Guiding Principles for Research Involving Animals and Human Beings" of the American Physiological Society (1).
Peptides
Rat PYY [rPYY ] was purchased from Phoenix Pharmaceuticals (Belmont, CA), and human PYY [hPYY(1-36)] was purchased from Bachem (Torrance, CA). Rat PYY [rPYY ] was synthesized and purified as follows.
Synthesis and Purification of rPYY(3-36)
5-(4-Fmoc-aminomethyl-3,5-dimethoxyphenoxy) valeric acid linker attached to a polyethylene-graft polystyrene support (PAL-PEG-PS) resin for solid-phase peptide synthesis was purchased from Applied Biosystems (Foster City, CA). O-(benzotriazol-1-yl)-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt), and protected amino acid derivatives were purchased from Chem-Impex International (Wood Dale, IL). Dimethylformamide (DMF), piperidine, trifluoroacetic acid (TFA), acetonitrile, and diethyl ether were purchased from Fisher Scientific (Pittsburgh, PA). Thioanisole, anisole, and ethanedithiol were purchased from Aldrich (St. Louis, MO).
rPYY was assembled by continuous flow solid-phase methodology on the PAL-PEG-PS support at a 0.1 mmol scale using a Pioneer Peptide Synthesizer (Foster City, CA). ␣-Amino groups were protected with the fluorenylmethoxycarbonyl (Fmoc) group and side chains were protected with the trityl group for Gln, His, and Asn; tert-butyl group for Ser, Asp, Glu, Thr and Tyr; tert-butyloxycarbonyl group for Lys; and pentamethyldihydrobenzofuransulfonyl group for Arg. After removal of the Fmoc group from the resin with 20% piperidine/DMF (vol/vol), HBTU-and HOBt-activated FmocTyr(tBu)-OH in DMF were coupled to the resin. This process was repeated with each amino acid derivative. After assembly, the peptideresin was washed with diethyl ether and dried under vacuum. Cleavage of peptide from the resin and removal of side chain protecting groups were accomplished in a 10-ml mixture of TFA, thioanisole, ethanedithiol, and anisole (9.0:0.5:0.3:0.2, vol/vol). After being stirred for 2 h at room temperature, the peptide was precipitated by the addition of cold diethyl ether. The peptide/resin was filtered. The peptide was dissolved in TFA, reprecipitated in cold diethyl ether, and isolated by filtration and lyophilized.
Purification of rPYY was accomplished by reverse-phase high-performance liquid chromatography on a Waters (Milford, MA) model 600 HPLC system. The crude peptide was dissolved in 78% solvent A (0.1% TFA/water) and 22% solvent B (0.095% TFA/ acetonitrile) and subjected to a gradient of 22% B to 34% B over 50 min on a semipreparative Vydac (Hesperia, CA) C 18 column (10 ϫ 250 mm). Flow rate was 4 ml/min, and the peptide was detected by UV absorbance at 230 nm. Fractions containing the pure peptide were collected and lyophilized. Proof of structure was provided by electrospray mass spectrometry.
Surgical Procedures
The procedures for implantation of jugular vein catheters for peptide infusions have been described previously (48) . The catheters were kept patent by flushing with 0.2 ml of 50% dextrose on alternate days and plugged with stainless steel wire. The rats were also implanted with gastric cannulas using established procedures (43) . The gastric cannulas were used for instilling saline containing the nonabsorbable marker phenol red and for collecting the gastric contents. The animals were allowed at least 1 wk to recover from surgery and adapted to restraint in Bollman cages before being subjected to experimentation. All gastric emptying studies were conducted on rats that were food deprived for at least 18 h but with free access to water. At the end of each experiment, the patency of the jugular vein catheters was determined by intravenous infusion of 0.2 ml of the short-acting anesthetic Propoflo (Abbott Laboratories). The catheters were considered patent if the rats lost consciousness immediately on injection of the anesthetic; only data from such propoflo-positive rats were included in statistical analyses.
Experiments Effects of intravenous infusion of rPYY(1-36) on gastric emptying.
On experimental days, the fasted rats were restrained in Bollman cages, gastric cannulas were opened, and residual gastric contents were flushed with warm water. The rats were then infused intravenously for 20 min with a single dose of rPYY(1-36) (0, 1.7, 5, 17, 50, 100, or 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 in 0.15 M NaCl, 0.1% BSA). Ten minutes after the onset of infusion, 5 ml of 0.9% saline containing 60 mg/l phenol red was instilled into the stomach. Ten minutes later, gastric contents were collected, the stomach was flushed with 5 ml of 0.9% saline, the flushings were combined with the gastric contents, and the total volume collected was measured gravimetrically. The concentration of phenol red in the instilled and recovered fluid was determined spectrophotometrically, and the volume of saline emptied during the 10-min period was calculated. Each rat (n ϭ 12) received each dose of rPYY in random order at ϳ48-h intervals. During the intervening days between experiments, the rats had free access to rat chow and a liquid diet (1.5 kcal/ml Ensure Plus, Abbott Laboratories).
Effects of intravenous infusions of rPYY and hPYY on gastric emptying. With the use of identical procedures as described above for rPYY , gastric emptying was measured in rats (n ϭ 12) receiving intravenous doses of rPYY(3-36) (0, 0.5, 1.7, 5, 17, 50, 100, and 170 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 in 0.15 M NaCl, 0.1% BSA) in random order at ϳ48-h intervals. For determining the effects of the human homologue of rPYY , gastric emptying was determined in rats (n ϭ 12) receiving intravenous doses of hPYY(3-36) (0, 17, and 50 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 in 0.15 M NaCl, 0.1% BSA) in random order at ϳ48-h intervals.
Effects of coadministration of rPYY and rPYY on gastric emptying. The experimental procedures were essentially the same as described above for rPYY and rPYY . Five experiments were performed to determine the effects of coadministration of different dose combinations of rPYY(1-36) and rPYY(3-36) on volume of saline emptied from the stomach. In one such experiment, rats (n ϭ 12) received in a randomized order, at ϳ48-h intervals, intravenous infusions of vehicle (0.15 M NaCl, 0.1% BSA) and (in pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) 1.7 of rPYY(1-36), 1.7 of rPYY(3-36), and 1.7 of rPYY(1-36) combined with 1.7 of rPYY . In the other experiments of identical design, rats received dose combinations (in pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) of 17 of rPYY(1-36) and 5 of rPYY(3-36), 50 of rPYY(1-36) and 17 of rPYY , 170 of rPYY(1-36) and 5 of rPYY , and 170 of rPYY(1-36) and 17 of rPYY .
Statistical Analysis
Values are presented as group means Ϯ SE. Data from each of the experiments determining the dose-response effects of rPYY , rPYY , and hPYY(3-36) on gastric emptying were analyzed separately by one-way repeated-measures ANOVA. Data from each of the experiments determining the effects of coadministration of rPYY(1-36) and rPYY(3-36) on gastric emptying were analyzed by a two-way repeated-measures ANOVA. Planned comparisons of treatment means were evaluated by paired t-tests; differences were considered significant if P Ͻ 0.05. A general nonlinear, least-squares curve fitting method was used to fit the dose-response data for the effects of rPYY(1-36) and rPYY(3-36) on gastric emptying to the following sigmoidal dose-response equation:
}; where Y is the response, X is the logarithm of the administered dose, a is the response for 0 dose, d is the response for infinite dose, c is the logarithm of the dose producing a response halfway between a and d (ED 50) , and b denotes the steepness of the dose-response curve. The ED50s for rPYY and rPYY(3-36) were compared as described previously (33) .
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on Gastric Emptying
Intravenous infusion of rPYY(3-36) dose dependently reduced the volume of saline emptied from the stomach ( Fig. 1;  F 
Ϫ1 ⅐min Ϫ1 compared with the vehicle-infused control group (3.48 Ϯ 0.14 ml). Nonlinear regression fitting of the dose-response data to the sigmoidal equation gave the following relationship between rPYY(3-36) and gastric emptying: volume emptied (ml) ϭ 2.54/{1 ϩ 10 [(1.57 Ϫ X) ⅐ Ϫ0.92] } ϩ 0.96, (r 2 ϭ 0.76) (Fig. 1) . The estimated ED 50 was 37 pmol⅐kg Ϫ1 ⅐min Ϫ1 , which was an order of magnitude lower than that for rPYY(1-36) (F 1,158 ϭ 42.9, P Ͻ 0.0001). The minimal and maximal effective doses of rPYY , and their inhibition of gastric emptying, were 5 pmol⅐kg Ϫ1 ⅐min Ϫ1 (10%) and 170 pmol⅐kg Ϫ1 ⅐min Ϫ1 (57%), respectively.
Intravenous infusion of hPYY(3-36) dose dependently reduced the volume of saline emptied from the stomach ( Fig. 1 ; F 2,30 ϭ 30.7, P Ͻ 0.0001). Compared with the vehicle-infused control group, the volume of saline emptied from the stomach was significantly decreased by 35 and 53% in response to 17 and 50 pmol⅐kg Ϫ1 ⅐min Ϫ1 of hPYY , respectively. The same doses of rPYY(3-36) produced comparable reductions in gastric emptying.
Effects of Coadministration of rPYY(1-36) and rPYY(3-36) on Gastric Emptying
Intravenous infusion of subthreshold doses of rPYY and rPYY , at 1.7 pmol⅐kg Ϫ1 ⅐min Ϫ1 each, had no significant effect on gastric emptying of saline when given alone or combined (Fig. 2A) . The main effects for rPYY(1-36) (F 1,9 ϭ 2.25, P Ͼ 0.05) and rPYY(3-36) (F 1,9 ϭ 0.07, P Ͼ 0.05), and the interaction between them (F 1,9 ϭ 0.05, P Ͼ 0.05), were not significant.
Intravenous infusion of near-threshold doses of rPYY(1-36) at 17 pmol⅐kg Ϫ1 ⅐min Ϫ1 and rPYY(3-36) at 5 pmol⅐kg Ϫ1 ⅐min Ϫ1 , alone and in combination, inhibited gastric emptying (Fig. 2B) . The main effects for rPYY(1-36) (F 1,11 ϭ 4.66, P Ͻ 0.05) and rPYY(3-36) (F 1,11 ϭ 8.47, P Ͻ 0.05) were significant, but the interaction between them was not significant (F 1,11 ϭ 0.53, P Ͼ 0.05). Relative to the vehicle-treated group, gastric emptying was significantly inhibited by 11% in response to rPYY(3-36) alone (P Ͻ 0.05) and 26% in response to coadministration of rPYY(1-36) and rPYY(3-36) (P Ͻ 0.05). The response to rPYY(1-36) alone was not quite significant (P ϭ 0.06). The response to coadministration of rPYY(1-36) and rPYY(3-36) was not different from the response to rPYY(3-36) alone.
Intravenous infusion of suprathreshold doses of rPYY(1-36) at 50 pmol⅐kg Ϫ1 ⅐min Ϫ1 and rPYY(3-36) at 17 pmol⅐kg Ϫ1 ⅐ min
Ϫ1
, alone and in combination, significantly inhibited gastric emptying (Fig. 2C) . The main effects for rPYY(1-36) (F 1,11 ϭ 5.93, P Ͻ 0.05) and rPYY(3-36) (F 1,11 ϭ 26.67, P Ͻ 0.001) as well as the interaction between them (F 1,11 ϭ 11.24, P Ͻ 0.01) were significant. Compared with the vehicle-treated group, gastric emptying was inhibited by 25% in response to rPYY(1-36) alone Fig. 2 . Effects of intravenous infusions of different doses of rat PYY(1-36) and rat PYY(3-36) alone, and in combination, on gastric emptying in rats. The doses (in pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) used were 1.7 rPYY (1-36) and 1.7 rPYY(3-36) (n ϭ 10) (A), 17 rPYY (1-36) and 5 rPYY(3-36) (n ϭ 12) (B), 50 rPYY (1-36) and 17 rPYY(3-36) (n ϭ 12) (C), 170 rPYY (1-36) and 5 rPYY(3-36) (n ϭ 10) (D), and 170 rPYY (1-36) and 17 rPYY(3-36) (n ϭ 9) (E). The peptides or vehicle (0.1% BSA/saline) was infused intravenously for 20 min in rats food deprived for 18 h. At 10 min after the onset of infusion, 5 ml of saline containing phenol red was instilled intragastrically, followed by collection of gastric contents 10 min later. Each column represents the mean Ϯ SE of the volume of saline emptied from the stomach. Treatment means with different letters were significantly different (a, b, c: P Ͻ 0.05).
(P Ͻ 0.001), 31% in response to rPYY(3-36) alone (P Ͻ 0.0001), and 30% in response to coadministration of rPYY and rPYY(3-36) (P Ͻ 0.001). The response to coadministration of rPYY and rPYY was not different from the individual responses to rPYY and rPYY .
Intravenous infusion of a suprathreshold dose of rPYY(1-36) at 170 pmol⅐kg Ϫ1 ⅐min Ϫ1 and a near-threshold dose of rPYY(3-36) at 5 pmol⅐kg Ϫ1 ⅐min
, alone and in combination, significantly inhibited gastric emptying (Fig. 2D) . The main effects for rPYY(1-36) (F 1,9 ϭ 14.73, P Ͻ 0.01) and rPYY (F 1,9 ϭ 12.53, P Ͻ 0.05), as well as the interaction between them (F 1,9 ϭ 13.69, P Ͻ 0.01), were significant. Relative to the vehicle-treated group, gastric emptying was inhibited by 27% in response to rPYY(1-36) alone (P Ͻ 0.001), 15% in response to rPYY alone (P Ͻ 0.01), and 23% in response to coadministration of rPYY and rPYY(3-36) (P Ͻ 0.01). The response to coadministration of rPYY(1-36) and rPYY(3-36) was not different from the individual responses to rPYY(1-36) and rPYY .
Intravenous infusion of suprathreshold doses of rPYY(1-36) at 170 pmol⅐kg Ϫ1 ⅐min Ϫ1 and rPYY(3-36) at 17 pmol⅐kg Ϫ1 ⅐min
, alone and in combination, significantly inhibited gastric emptying (Fig. 2E) . The main effects for rPYY(1-36) (F 1,8 ϭ 12.69, P Ͻ 0.01) and rPYY(3-36) (F 1,8 ϭ 9.11, P Ͻ 0.05), as well as the interaction between them (F 1,8 ϭ 20.44, P Ͻ 0.01), were significant. Relative to the vehicle-treated group, gastric emptying was inhibited by 41% in response to rPYY(1-36) alone (P Ͻ 0.001), 37% in response to rPYY(3-36) alone (P Ͻ 0.001), and 37% in response to coadministration rPYY(1-36) and rPYY(3-36) (P Ͻ 0.001). The response to coadministration of rPYY(1-36) and rPYY(3-36) was not different from the individual responses to rPYY(1-36) and rPYY .
DISCUSSION
We demonstrate here that intravenous infusion of rPYY and rPYY(3-36) each produces a dose-dependent inhibition of gastric emptying in rats. Minimal effective doses were 17 and 5 pmol⅐kg Ϫ1 ⅐min Ϫ1 , ED 50 s were 470 and 37 pmol⅐kg Ϫ1 ⅐min
Ϫ1
, and maximal effective doses (170 pmol⅐kg Ϫ1 ⅐min Ϫ1 each) inhibited gastric emptying by 38 and 57%, respectively. Thus rPYY is an order of magnitude more potent than rPYY(1-36) in reducing gastric emptying in rats. Our results also suggest that hPYY(3-36) and rPYY , which differ by two amino acids at positions 3 and 18 (20, 28) , inhibit gastric emptying in rats with a similar potency and efficacy. We have used the same experimental model to determine the dose-dependent effects of CCK-8, amylin, calcitonin (CT), salmon CT (sCT), CT-gene-related peptide (CGRP), and adrenomedullin (ADM) on gastric emptying (41, 42) . Our results suggest an order of potency of sCT Ͼ amylin Ͼ CCK-8 ϭ PYY(3-36) Ͼ CGRP ϭ ADM Ͼ PYY(1-36) Ͼ CT (estimated ED 50 , respectively). In rats, intravenous PYY(1-36) infusion at doses from 0.83 to 2 pmol⅐kg Ϫ1 ⅐min Ϫ1 appear to increase plasma PYY by an amount comparable to that produced by a mixed-nutrient liquid meal (26, 46) . In the present study, intravenous infusion of PYY(1-36) at 1.7 and 5 pmol⅐kg Ϫ1 ⅐min Ϫ1 had no effect on gastric emptying; the minimal effective dose was 17 pmol⅐kg Ϫ1 ⅐min Ϫ1 . Together, these results suggest that postprandial levels of PYY(1-36) are not sufficient to inhibit gastric emptying in rats. The intravenous doses of PYY(3-36) that reproduce meal-induced increases in plasma PYY(3-36) have not been determined for rats. Thus it is unknown whether postprandial plasma levels of PYY are sufficient to inhibit gastric emptying. It also remains to be determined whether circulating PYY(1-36) or PYY interact with other factors to inhibit gastric emptying, or whether these peptides act by neurocrine or paracrine mechanisms, rather than endocrine mechanisms, to inhibit gastric emptying. Raybould et al. (40) provided evidence suggesting that PYY is not an essential mediator of the inhibitory effect of intestinal lipid on gastric emptying in rats. Intraperitoneal injection of PYY antiserum blocked the inhibitory effect of intraperitoneal injection of PYY(1-36) on gastric emptying but had no effect on gastric emptying responses to lipid administration into the proximal or distal small intestine. However, the extent to which the PYY antiserum bound PYY(3-36) was not determined.
Our results indicate that PYY(3-36) is an order of magnitude more potent than PYY(1-36) in reducing gastric emptying in rats. Possible reasons for this difference in potency include differences in plasma clearance rates, access to target tissues (e.g., brain uptake), and receptor binding properties of the two PYY analogs. PYY and PYY appear to have similar plasma half-lives of 8 to 12 min in dogs (21, 31, 39) . Plasma half-lives of PYY and PYY in rats, and the relative blood-brain barrier permeabilities of each peptide, remain to be determined. The enzyme dipeptidyl-peptidase IV (DPP IV) cleaves the NH 2 -terminal Tyr-Pro of PYY to yield PYY(3-36) (35) . DPP IV is located on the endothelial cells of blood vessels as a soluble enzyme in plasma and in a number of other tissues (34) . The extent to which PYY(1-36) is converted to PYY(3-36) on entering the circulation has not been determined. Our results suggest that the effects of PYY(1-36) on gastric emptying are not solely mediated by its conversion to PYY ; otherwise, coadministration of PYY and PYY should have produced an additive effect on gastric emptying in the present study, which it did not (further discussed below).
The difference in potency of PYY and PYY in reducing gastric emptying may be due to differences in receptor binding properties of the two peptides. PYY and PYY (5, 28, 29) . It was postulated that differences in the tertiary structure of both forms likely explain the differences in their ligand binding affinities (28, 29) . The juxtaposition of both the amino and COOH termini of the molecule is required for Y 1 -receptor binding, whereas only the COOH-terminal helix confers selectivity for Y 2 -receptor binding (29) . PYY(1-36) contains both structural features, and hence it can bind both Y 1 and Y 2 receptors. The cleavage of the amino terminal dipeptide from PYY to form PYY eliminates the juxtaposition of the amino and COOH termini, resulting in reduced binding of PYY to the Y 1 -receptor (29) . It is likely that this tertiary structure is conserved in both rat and hPYY , which might explain their similar potencies in inhibiting gastric emptying in rats.
Several lines of evidence suggest that circulating PYY gains access to the dorsal vagal complex (DVC) to activate Y 2 receptors on vagal efferents to inhibit gastric emptying. Findings include 1) peripherally administered PYY (1-36) binds in a saturable manner to specific areas in the DVC (23) and induces c-Fos immunoreactivity in these areas (6); 2) PYY(1-36) and NPY(3-36) (a Y 2 agonist) dose dependently inhibit excitatory postsynaptic currents in cholinergic neurons of the dorsal motor nucleus of the vagus (10); 3) injection of PYY or Y 2 agonists [NPY or PYY ] into the DVC inhibits neurons of the dorsal motor nucleus of the vagus, as well as TRH-induced gastric motility (11, 12, 14) ; 4) intracisternal injections of PYY(1-36) inhibit gastric emptying, and this inhibition is attenuated by vagotomy (13); and 5) intracerebroventricular injection of NPY(3-36) (Y 2 agonist) dose dependently delays gastric emptying of solids, as well as impairs antral contractions and antropyloric coordination in the emptying period (25) . In contrast to these Y 2 receptor-dependent effects, Y 1 receptor-mediated effects on gastric emptying appear to be stimulatory. Central administration of the Y 1 agonist (Leu 31 , Pro 34 ) NPY was shown to stimulate gastric motility under basal conditions without further augmenting TRH-stimulated gastric motility in rats (14) . These results together with our finding that PYY(3-36) is more potent than PYY(1-36) in inhibiting gastric emptying, suggest that PYY(1-36) and PYY(3-36) may each stimulate a Y 2 receptor-mediated inhibition of gastric emptying, whereas PYY(1-36) might also activate a Y 1 receptor-mediated stimulation of gastric emptying, which partially counteracts its action at Y 2 receptors to inhibit gastric emptying.
The studies just cited provide strong evidence that PYY(3-36), acting by a hormonal mechanism, gains access to the DVC to activate Y 2 receptors on vagal efferents to inhibit gastric emptying. In addition to this central mechanism, it is also possible that PYY(3-36) interacts directly with Y 2 receptors along the gastrointestinal tract to decrease gastric emptying. The mRNA for Y 2 receptors has been detected in the intestine of rats (18) , and activation of colonic Y 2 receptors has been reported to increase longitudinal smooth muscle tone in human and mouse colon (24) . In addition to these possible endocrine mechanisms, the presence of PYY immunoreactivity in the gastric mucosa and enteric nervous system (15) suggests that PYY(3-36) might also act by paracrine or neurocrine mechanisms to inhibit gastric emptying.
In contrast to our results, Batterham et al. (4) reported that PYY(3-36) had no effect on gastric emptying in rats or humans. However, PYY(3-36) dosing and methods of measuring gastric emptying were not adequately described in that article to permit speculation on why this discrepancy has occurred.
Because PYY(1-36) and PYY coexist in the circulation, our interest was in determining whether these peptides interact in an additive or synergistic manner to inhibit gastric emptying. Five different doses of PYY were paired with three different doses of PYY . Five combinations of PYY and PYY ). In general, coadministration of PYY and PYY inhibited gastric emptying by an amount that was comparable to the inhibition produced when either peptide was given alone. The apparent lack of additivity or synergy between PYY(1-36) and PYY In summary, the present study demonstrates that 1) intravenous infusion of PYY and PYY(3-36) each produces a dose-dependent inhibition of gastric emptying in rats, 2) PYY(3-36) is an order of magnitude more potent than PYY in inhibiting gastric emptying, 3) hPYY(3-36) and rat PYY(3-36) inhibit gastric emptying similarly, and 4) PYY(1-36) and PYY(3-36) do not appear to interact in an additive or synergistic manner to inhibit gastric emptying. It remains to be determined whether endogenous molecular forms of PYY act by endocrine, paracrine, and/or neurocrine mechanisms to decrease gastric emptying; whether PYY inhibits gastric emptying of solid food; and whether PYY inhibits gastric emptying during as well as after gastric filling.
